The company’s president and head of research and development, Dr Maria Grazia Roncarolo, is leading the trial.

Hany Elmariah, MD, discusses incorporating fedratinib as maintenance therapy in the posttransplant setting to prevent relapse of MPNs and graft-vs-host disease.

The ACCESS trial is a multicenter, phase 2 trial designed to compare overall survival in patients receiving mismatched unrelated donor peripheral blood stem cells as an allograft source for ...

Kiji Therapeutics Engineered MSCs + IL-10 and CXCR4 offer tighter targeting and greater potency for challenging inflammatory diseases.

The University of Birmingham researchers have identified CD70 as a key target to reduce the risk of graft-versus-host disease (GVHD) in blood cancer patients post-stem cell transplant. GVHD causes ...

Tr1X awarded $8 million CIRM grant to support TRX103 phase 1/2a trial for graft-versus-host disease: San Diego Monday, April 7, 2025, 11:00 Hrs [IST] Tr1X, Inc. (Trix), a clinical ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

The addition of post-transplant cyclophosphamide to sirolimus and cyclosporine reduced chronic GVHD. Efforts are needed to optimize cyclophosphamide dose to reduce toxicity. A novel regimen ...

In the study, which enrolled 187 patients with four different types of leukemia, the T cell therapy called Orca-T reduced the risk of chronic graft versus host disease (GVHD) by 74% compared to a ...

Considering taking supplements to treat graft versus host disease gvhd? Below is a list of common natural remedies used to treat or reduce the symptoms of graft versus host disease gvhd.

These include rejection and failure of the transplanted cells and graft-vs.-host disease, or GVHD, and the discovery that grafted donor immune cells play a pivotal role in eliminating the patient’s ...